Abstract:

Objective　To analyze the efficacy of Xiangdan injection combined with metoprolol tartrate in patients with coronary heart disease and angina pectoris, as well as its impact on clinical symptoms and oxidative stress response. Methods　A total of 92 patients with angina pectoris of coronary heart disease who were admitted to Shangqiu Municipal Hospital from April 2021 to April 2024 were selected as the research subjects. The patients were divided into the control group (46 cases) and the research group (46 cases) by using the random number table method. There were 25 males and 21 females in the control group, aged 51-78(64.29±7.08) years, course of coronary heart disease 2-10(6.24±1.66) years. There were 22 males and 24 females in the research group, aged 52-79(65.36±7.17) years, course of coronary heart disease 2-11(6.51±1.84) years. The control group was treated with metoprolol tartrate, and the research group was treated with Xiangdan injection combined with metoprolol tartrate. Compare the clinical efficacy of the two groups; clinical symptoms (frequency and duration of angina pectoris attacks), levels of myocardial injury markers [creatine kinase MB (CK-MB), brain natriuretic peptide (BNP), cardiac troponin Ⅰ (cTnⅠ)], and oxidative stress indicators [superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA)] before and after treatment; and adverse reactions (vertigo, nausea, fatigue, etc.). Independent sample t test, paired t test, and χ² test were used for statistical analysis. Results　The total effective rate of treatment in the research group was higher than that in the control group[89.13% (41/46) vs. 71.74% (33/46)](P<0.05). After the treatment, the frequency of angina pectoris attacks in the research group was lower than that in the control group[(2.49±0.62) times/week vs. (3.25±0.68) times/week] and the duration of angina pectoris was shorter than that of the control group[(5.05±0.97) min vs. (6.54±0.39) min] (both P<0.05); the levels of BNP, CK-MB and cTnⅠ in the research group were lower than those in the control group [(114.72±16.87) ng/L vs. (143.59±18.04) ng/L, (15.27±2.21) U/L vs. (18.67±2.16) U/L, (1.21±0.27) μg/L vs. (1.46±0.26) μg/L] (all P<0.05); the MDA level in the research group was lower than that in the control group [(6.24±1.29) mol/L vs. (8.27±1.46) mol/L] and the levels of CAT and SOD were higher than those of the control group [(34.97±4.38) U/ml vs. (30.67±4.21) U/ml, (98.46±7.64) U/L vs. (90.37±7.92) U/L](all P<0.05). There were no statistically significant difference in the total incidence rate of adverse reactions between the two groups (P>0.05). Conclusion　Xiangdan injection combined with metoprolol tartrate has significant effect in treating angina pectoris in coronary heart disease, which helps to improve the symptoms of angina pectoris, reduce oxidative stress damage, improve myocardial damage, and has high safety.

摘要：

目的　分析香丹注射液联合酒石酸美托洛尔治疗冠心病心绞痛患者的效果，及其对临床症状和氧化应激反应的影响。方法　选取2021年4月至2024年4月商丘市立医院收治的92例冠心病心绞痛患者作为研究对象。采用随机数字表法，将患者分为对照组（46例）和研究组（46例）。对照组男25例，女21例；年龄51～78（64.29±7.08）岁；冠心病病程2～10（6.24±1.66）年。研究组男22例，女24例；年龄52～79（65.36±7.17）岁；冠心病病程2～11（6.51±1.84）年。对照组采用酒石酸美托洛尔治疗，研究组采用香丹注射液联合酒石酸美托洛尔治疗。比较两组临床疗效；治疗前后临床症状（心绞痛发作频率、持续时间）、心肌损伤标志物［脑钠肽（BNP）、肌酸激酶同工酶（CK-MB）、心肌肌钙蛋白Ⅰ（cTnⅠ）］和氧化应激指标［丙二醛（MDA）、过氧化氢酶（CAT）、超氧化物歧化酶（SOD）］水平；不良反应（头晕、恶心、疲劳等）。采用独立样本t检验、配对t检验和χ2检验进行统计学分析。结果　研究组治疗总有效率高于对照组［89.13%（41/46）比71.74%（33/46）］（P<0.05）。治疗后，研究组心绞痛发作频率低于对照组［（2.49±0.62）次/周比（3.25±0.68）次/周］，心绞痛持续时间短于对照组［（5.05±0.97）min比（6.54±0.39）min］（均P<0.05）；研究组BNP、CK-MB、cTnⅠ水平均低于对照组［（114.72±16.87）ng/L比（143.59±18.04）ng/L、（15.27±2.21）U/L比（18.67±2.16）U/L、（1.21±0.27）μg/L比（1.46±0.26）μg/L］（均P<0.05）；研究组MDA水平低于对照组［（6.24±1.29）mol/L比（8.27±1.46）mol/L］，CAT和SOD水平均高于对照组［（34.97±4.38）U/ml比（30.67±4.21）U/ml、（98.46±7.64）U/L比（90.37±7.92）U/L］（均P<0.05）。两组不良反应总发生率比较，差异无统计学意义（P>0.05）。结论　香丹注射液联合酒石酸美托洛尔治疗冠心病心绞痛患者效果较好，有助于改善临床症状，减轻氧化应激损伤，改善心肌受损状况，安全性较好。

关键词: 冠心病心绞痛,  ,  , 香丹注射液,  ,  , 酒石酸美托洛尔,  ,  , 临床症状,  ,  , 氧化应激